Michael Gold, M.D.

Michael Gold is the chief medical officer of Neumora. Dr. Gold brings over 20 years of pharmaceutical industry experience across all stages of CNS drug development. Most recently, he served as Vice President, Therapeutic Head CNS Development at AbbVie, where he was responsible for AbbVie’s CNS pipeline and led a group of approximately 40 physicians and scientists focused on conducting clinical development. Prior to joining AbbVie, Dr. Gold held leadership positions at a number of biopharmaceutical companies, including Bristol Myers Squibb, Johnson & Johnson, GlaxoSmithKline, UCB and PPD, Inc.

Dr. Gold serves as the non-voting Industry Representative to the U.S. Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee. He has served on a number of Scientific Advisory Boards for biotechnology companies and patient advocacy foundations and serves as a grant reviewer for several philanthropic organizations. In addition, Dr. Gold serves as an editor and reviewer for several peer-reviewed medical journals and has authored approximately 50 peer-reviewed publications.

Dr. Gold holds an M.D., an M.S in Mathematics and Computer Science, and a B.S. in Chemistry, all from the University of Miami. He completed a Neurology residency at the Albert Einstein College of Medicine in New York and a fellowship in Behavioral Neurology at the University of Florida College of Medicine. After completing his training, Dr. Gold was appointed as an Assistant Professor in the Department of Neurology at the University of South Florida, where he also served as the Medical Director for the Memory Disorder Clinic.